PTC Therapeutics director files initial Form 3

PTC Therapeutics, Inc. director Jessica Caroline Chutter filed an initial Form 3, which is a required statement of beneficial ownership for new insiders.

Rhea-AI Filing Summary

PTC Therapeutics, Inc. director Jessica Caroline Chutter filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. The filing does not list any stock transactions or holdings details in the provided data, and serves as a baseline disclosure of her insider status.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PTC Therapeutics (PTCT) Form 3 filing for Jessica Caroline Chutter show?

The Form 3 filing shows that Jessica Caroline Chutter is a director of PTC Therapeutics. It serves as her initial statement of beneficial ownership, and the provided data includes no reported stock transactions or detailed holdings information.

Does the PTCT Form 3 for Jessica Caroline Chutter report any stock purchases or sales?

No stock purchases or sales are reported in this Form 3. The transaction section is empty in the provided data, indicating this filing functions purely as an initial ownership disclosure rather than documenting trading activity.

Why is Jessica Caroline Chutter filing a Form 3 for PTC Therapeutics (PTCT)?

Form 3 is required when someone becomes an insider, such as a director, of a public company. This filing records Jessica Caroline Chutter’s status as a director of PTC Therapeutics and establishes a starting point for future ownership and trading disclosures.

Does the PTCT Form 3 include any derivative securities for Jessica Caroline Chutter?

The derivative section in the provided data is empty, so no options or other derivative securities are shown. This means only her insider status is documented here, without any listed derivative positions tied to PTC Therapeutics.

What can PTCT investors learn from Jessica Caroline Chutter’s Form 3?

Investors can see that Jessica Caroline Chutter is now a director and therefore a reporting insider at PTC Therapeutics. The filing itself does not indicate buying or selling activity, but it establishes that future transactions must be reported on Forms 4 or 5.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 07:39 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chutter Jessica Caroline

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/24/2026

3. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Avraham S. Adler, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)